Trial Profile
Prospective, Multicenter, Randomized, Evaluating Two Induction Therapies With Simulect Versus ATG Fresenius Associated With Tacrolimus and Myfortic in the Prevention of Treatment Failure, in Sensitized Renal Transplant
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Antilymphocyte globulin (Primary) ; Basiliximab (Primary) ; Corticosteroids; Mycophenolate sodium; Tacrolimus
- Indications Graft-versus-host disease; Renal transplant rejection
- Focus Therapeutic Use
- Acronyms SATIR
- 07 May 2017 Status changed from recruiting to completed.
- 06 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 06 May 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.